The Online International Journal of Onco Scientific Networks & Oncology is a peer-reviewed open acess journal that publishes original research articles as well as review articles in all areas of Oncology. this practical journal also includes information on new products, new therapies and patient management, as well as reviews of the latest research. Cancer is a complex problem. The international effort to understand and control it involves clinicians trained in many branches of medicine and scientists from most biological disciplines, chemistry, pharmaceutical and physical sciences The International Online Journal of Cancer & Therapeutics exists to serve the needs of this diverse community, providing a forum for prompt communication of original and innovative research findings that have relevance to understanding the etiology of cancer and to improving the treatment and survival of patients.
The journal publishes important original studies, reviews, and perspectives within the major topic areas of biology of premalignancy, risk factors and risk assessment, early detection research, immunoprevention, and chemopreventive and other interventions, including the basic science behind them. This journal comprises preclinical, clinical and translational research, with special attention given to molecular discoveries and an emphasis on building a translational bridge between the basic and clinical sciences. Main focuses of interest include: systemic anticancer therapy (with specific interest on molecular targeted agents and new immune therapies), randomized trials (including negatives ones), top-level guidelines, and new fields currently emerging as key components of personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Radiotherapy, surgery and pediatrics manuscripts can be considered if they display a clear interaction with one of the fields above or are paradigm-shifting.
Oncology is the diagnosis and treatment of cancers,including breast,prostate,colon,lung and ovarian cancers as well as brain tumors,leukemia,lymphoma and many other types of cancer.. A doctor who works in the field of oncology is called an oncologist. The primary regions of oncology are radiation, which is worried with radiation treatment, or radiotherapy; surgical, which is contained specialists who spend significant time in tumor evacuation; therapeutic, which manages disease drugs, including chemotherapy; and interventional, which includes interventional radiologists who have some expertise in insignificantly obtrusive picture guided tumor treatment.
It is our pleasure to welcome you on behalf of the editorial board members,Professors,Scientists... it is with great pleasure, humility and honour that we welcome you to this inaugural first issue of Journal of Cancer & Therapeutics. Hosted by the Helics Scientific Networks and Cancer Leadership 2018.
The journal has a strong emphasis on interdisciplinary issues reflecting the complexity of Cancer & Therapeutics. Today, Cancer & Therapeutics are a very broad research area involving different scientific disciplines ranging , to basic sciences and from medicine to marketing. In each of this areas there are different journals dealing with very specific aspects intended for a limited audience. Similarly, interdisciplinary researches are often difficult to publish in specialized journals and part of the aim of Journal of Cancer & Therapeutics is to capture high-quality works that doesn’t clearly fall within the scope of other journals. This openminded stance toward the scope of the journal allows to overcome knowledge fragmentation and the integration between apparently different topics providing the reader with a global view on the topic of interest.
We delighted to be a part of this new interdisciplinary initiative, which we believe is exactly the type of platform needed to highlight and broaden Cancer & Therapeutics into widespread acceptance with the highest values of scientific integrity to which the Journal of Cancer & Therapeutics is inspired.
Once more, on behalf I welcome you to this journal. We look forward to your submissions and to publish your manuscripts.
The Online International Journal of Onco Scientific Networks & Oncology aims to publish scientific articles in General Medicine. It covers the entire spectrum from basic science to clinical medicine, including research papers, case reports and review articles as special articles.
For scientific research work constantly, but also an integrative review of all the work and results obtained in relation to a particular topic that will generate a real knowledge about that is not only necessary.
Track: 1 Cell and Tumor Biology
Track: 2 Carcinogenesis
Track: 3 Cancer Genomics, Epigenetic and Genomic Instability
Track: 4 Prevention and Early Detection
Track: 5 Radio-biology / Radiation Oncology
Track: 6 Molecular Pathology Approach to Cancer
Track: 7 Molecular and Genetic Epidemiology
Track: 8 Experimental / Molecular Therapeutics, Pharmacogenomics
Track: 9 Cancer Research & Cancer Metabolism
Track: 10 Intraoperative Imaging Technologies for Cancer Detection and Treatment
Track: 11 Methods in Clinical Cancer Research
Track: 12 Tumour Immunology
Track: 13 Paradigms in Interventional Pulmonology Ultrasound & Lung Cancer Staging
Track: 14 Uro Oncology
Track: 15 Cancer Nursing
Track: 16 Gastrointestinal (GI) Cancer
Track: 17 Gynaecological Oncology
Track: 18 Breast Cancer
Track: 19 Cancer Vaccines and Immunoengineering
Track: 20 Lung Cancer
Cancer Scientific Networks:
Cancer Leadership & Committees consider proposals for Special Issues Editors will return a decision on your proposal within Two weeks of receipt. To enrich our vision of making the scientific information available at an ease of access, Cancer Leadership & Committees initiated special issue for the open access journals. All the articles published under a special issue focuses on a single topic providing the complete information about the ongoing research providing more insight on an emphasized topic of research enabling the readers access wide forecasted information on a particular topic Issue.
Special Issue Proposals: Special Issue deals with focused research topics of high interest, falling under the scope of the Journal. Special Issues are the pool of articles under a current topic selected from the Ongoing Research under specific discipline. The aim of the Special Issue is to provide a platform for the researchers to understand the recent advancements and challenges in particular areas of research. These articles will provide an opportunity to the readers to understand and access the scientific information.
We encourage potential scientists to organize the Special Issue in their field of interests that fits within the Journal scope. This will provide an opportunity to increase the visibility of the Guest Editors. The Special Issue Titles may be from any basic and clinical area of Science, Technology and Medicine. People interested in publishing a special issue are advised to consider the following guidelines.
Your proposal should contain:
By submitting a Special Issue proposal to Cancer Leadership & Committees, you agree to abide by the Special Issue Editor Protocol should your proposal be accepted
Special issue articles are published immediately upon their acceptance and are released under upcoming regular issues. Special Issues are invited throughout the year. For more information or any queries about the special issues, please write us to firstname.lastname@example.org or email@example.com
Promoting Your Special Issue
Cancer Leadership & Committees will work with Guest Editors to increase the visibility of the Special Issue in the months leading up to the submission deadline and once it has been published.
What Cancer Leadership & Committees will do:
1. Cancer Leadership & Committees will circulate your Call for Papers to the Cancer Editorial Board, targeted mailing lists, and relevant AoM listservs. It will also advertise your Call on the Cancer websites and other social media platforms. It will re-issue the Call at appropriate intervals.
2. Once the Special Issue is published, announcements will be made to the Cancer Editorial Board, targeted mailing lists, and relevant AoM listservs as well as on the Cancer websites social media platforms.
3. Free access to the Special Issue will be made available in the website to Guest Editors and readers.
What is expected of Guest Editors?
1. We expect that Guest Editors will circulate the Call for Papers within their own personal networks, social media groups, and at any relevant conferences or workshops they may attend.
2. If it has not already been suggested as part of the proposal, consideration should be given to organizing a conference or workshop either to generate submissions or to aid in the development of submitted papers. A symposium or PDW at a well-known conference may also be considered.
3. We expect Guest Editors to identify up to 50 scholars for whom the Special Issue will be particularly relevant
If you have any queries, please contact Eliza Lind (Cancer.firstname.lastname@example.org)
2011.9-2014.6 - Ph.D, Urinary Surgery, the Second Clinical College, Wuhan University, Wuhan, China
Project Title: Mechanisms in resistance to Chemoradiotherapy of Prostate Cancer Stem Cells
2007.9-2010.7 - M.S, Oncology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Project Title: Prognostic Value of Thymidine Phosphorylase/Platelet-derived Endothelial Cell
Growth Factor and Thrombocytosis in Gastric Carcinoma
1997.9-2002.7 - B.S., Clinical Medicine, Wuhan University, Wuhan, China
 Wang L, Huang X, Zheng X, et al. Concurrent chemoradiotherapy with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Clin Transl Oncol, 2014, 16(6): 567-572.
 Wang L, Huang X, Zheng X, et al. Enrichment of Prostate Cancer Stem-Like Cells from Human Prostate Cancer Cell Lines by Culture in Serum-Free Medium and Chemoradiotherapy. Int J Biol Sci, 2013, 9(5): 472-479.
 Wang L, Huang X, Chen Y, et al. Prognostic value of TP/PD-ECGF and thrombocytosis in gastric
carcinoma. Eur J Surg Oncol, 2012, 38(7): 568-573.
 Huang X, Wang L, Zheng XM, Wang XH. Comparison of perioperative, functional, and
oncological outcomes between standard laparoscopic and robotic-assisted radical
prostatectomy: a systemic review and meta-analysis. Eur J Surg Oncol (manuscript number:
EJSO-D-16-00270), under review.
 Huang X, Wang L, Chen Y, Zheng XM, Wang XH. Poor prognosis associated with high levels of
thymidine phosphorylase and thrombocytosis in patients with renal cell carcinoma. Urologia
Internationalis. (on line)
 Huang X, Wang L, Wang XH, Shi HB, Zhang XJ, Yu ZY. Bipolar transurethral resection of the
prostate causes deeper coagulation depth and less bleeding than monopolar transurethral
prostatectomy. Urology, 80(5): 1116-1120, 2012.
 Wang L, Ning JF, Wakimoto H, Wu SL, Wu CL, Rabkin SD, Martuza RL. Oncolytic herpes simplex virus and phosphoinositide 3-kinase/Akt pathway inhibitor BKM120 synergize to promote killing of prostate cancer stem-like cells. (ready for submission)